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AbstrACt
Introduction Time is the most crucial factor limiting 
efficacy of intravenous thrombolysis (IVT) and intra-
arterial thrombectomy (IAT). The delay between alarming 
the Emergency Medical Services (EMS) dispatch office 
and IVT/IAT initiation, that is, the ‘total system delay’ 
(TSD), depends on logistics and team effort. A promising 
method to reduce TSD is real-time audio-visual feedback 
to caregivers involved. With ‘A Reduction in Time with 
Electronic Monitoring in Stroke’ (ARTEMIS), we aim to 
investigate the effect of real-time audio-visual feedback on 
actual TSD to IVT/IAT to caregivers.
Methods and analysis ARTEMIS is a multiregional, 
multicentre, randomised open end-point trial including 
patients ≥18 years considered IVT/IAT-eligible by the 
EMS dispatch office or on-site EMS personnel. Patients 
are electronically tracked and randomised for real-
time audio-visual feedback on TSD to caregivers via 
premounted handhelds and tablets throughout the TSD 
trajectory. Primary outcome is TSD to IVT/IAT. Secondary 
outcomes comprise proportion of IVT/IAT-treated patients, 
symptomatic intracerebral haemorrhage, IVT/IAT-treated 
stroke mimics, clinical outcome after three months and 
cost-effectiveness. Separate analyses for IAT-patients with 
or without prior IVT, within or out of office hours and EMS 
region will be performed. With 75 IAT-patients and 225 
IVT-patients in each arm, we will be able to demonstrate a 
20 min difference in TSD to IAT and a 10 min difference in 
TSD to IVT (p=0.05 and power=0.8).
Ethics and dissemination Study findings will be 
disseminated through peer-reviewed journals and (inter)
national conference presentations.
trial registration number NCT02808806; Pre-results.
IntroduCtIon 
For acute ischaemic stroke, the clinical benefit 
of intravenous thrombolysis (IVT) within 
4.5 hours and of intra-arterial thrombectomy 
(IAT) within 6 hours from symptom onset is 
firmly established.1–7 For both IVT and IAT, 
the passing of time is the most crucial factor 
limiting clinical effectiveness.8–10 For example, 
with every 15 min delay to treatment, the 
chances of independent ambulation substan-
tially decrease and 1 month of disability-free 
life is lost.2–6 8 11 12 Moreover, reducing treat-
ment delays will make IVT/IAT accessible 
for patients who would otherwise exceed the 
IVT/IAT time window. Therefore, reducing 
delay to IVT/IAT is of paramount impor-
tance. This has been substantiated by guide-
lines with the door-to-needle time (DNT) 
for IVT as an important practice and quality 
parameter,13 14 and this will likely transpire 
for the door-to-groin time (DGT) for IAT as 
well.15 
Since the introduction of IVT, median 
DNTs have been reduced, but further reduc-
tion is still possible.13 Reducing DGT appears 
logistically even more challenging. More 
caregivers are involved and IAT frequently 
requires interhospital transport.
Besides in-hospital delays, prehospital 
delays should be considered (eg, time spent 
on scene by Emergency Medical Services 
(EMS) personnel). These delays are often 
strengths and limitations of this study
 ► A Reduction in Time with Electronic Monitoring in 
Stroke is a multiregional, multicentre, randomised 
trial providing high external validity.
 ► The intervention establishes a unique connection 
in the chain of acute stroke care bridging the gap 
between separate prehospital and in-hospital care-
givers involved.
 ► The PROBE design is pragmatic and reflects stan-
dard clinical practice of acute stroke care.
 ► We anticipate that during the study period, treat-
ment delays will decrease due to initiatives aimed to 
optimise logistics other than our intervention.
 ► A carryover effect of the intervention cannot be fully 
excluded but is estimated to be unlikely since shifts 
of stroke teams occur multiple times a day.
 on 7 A









pen: first published as 10.1136/bm




2 Koster GT, et al. BMJ Open 2018;8:e020844. doi:10.1136/bmjopen-2017-020844
Open access 
less recognised and have scarcely diminished over the 
past decades,16–18 while relevant time reductions can be 
achieved.19–22 We will further refer to the entire (prehos-
pital and in-hospital) treatment trajectory that can be 
influenced by caregivers and depends on optimal logistics 
as the ‘total system delay’ (TSD), in analogy to the literature 
in cardiology (see figure 1).23
A promising method to reduce TSD is to provide real-
time audio-visual feedback to caregivers directly involved 
with the patient.
From the field of psychology, it is well established 
that awareness of being observed maximises dedication 
and efforts. This so-called ‘Hawthorne effect’ increases 
efficacy and leads to optimal workflow and streamlined 
care.24–26
Cohort studies have shown that feedback to caregivers 
reduces delays to IVT,27–29 but feedback was not provided 
real-time, prehospital delays were not accounted for and 
IAT was not standard of care at the time. The literature 
on feedback as a tool to reduce TSD in patients with 
acute myocardial infarction is more extensive and shows 
promising results.30 31 For example, in a recent Dutch 
study, real-time visual feedback was associated with a 
18 min reduction in TSD to percutaneous coronary 
intervention.32 However, this intervention was never 
randomised, leaving room for bias as other (logistic) 
factors could over time contribute to an improved 
process.
With our study, we aim to determine the efficacy of real-
time audio-visual feedback on TSD to IVT/IAT in patients 
presenting with acute ischaemic stroke.
MEthods
study design
A Reduction in Time with Electronic Monitoring In 
Stroke (ARTEMIS) is a multiregional, multicentre 
prospective randomised open-label blinded end-point 
(PROBE) trial, investigating if real-time audio-visual feed-
back to caregivers reduces TSD to IVT/IAT. The study 
is conducted in three both urban and peripheral EMS 
regions in the Netherlands, comprising over 2.5 million 
inhabitants. Each region contains one comprehensive 
stroke centre with IAT-availability and at least one local 
hospital treating over 30 IVT-patients per year.
We hypothesise that real-time audio-visual feedback to 
caregivers on actual TSD will reduce median TSD to IAT 
with at least 20 min and median TSD to IVT with at least 
10 min compared with regular care.
Figure 1 Treatment delays in acute ischaemic stroke care. CSC, comprehensive stroke centre; IAT, intra-arterial thrombectomy; 
IVT, intravenous thrombolysis; PSC, primary stroke centre; TSD, total system delay.
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study population
All patients≥18 years considered IVT/IAT-eligible by the 
EMS dispatch office or on-site EMS personnel, following 
regional EMS’ stroke algorithm.
Intervention
Real-time audio-visual feedback will be delivered through 
handhelds and tablets en route from ambulance to IVT/
IAT initiation. Real-time visual feedback on actual treat-
ment delays for the transferred patient will be shown to 
caregivers involved. Also, a colour code (green, orange 
or red) will provide an easy-view visualisation on whether 
or not preset median time delays between locations are 
exceeded. Additionally, on preset locations (eg, the emer-
gency room (ER), CT room and angiography suite), audi-
tory feedback broadcasting the elapsed time on preset 
moments (eg, every 3–5 min) will be installed.
In order to provide real-time audio-visual feedback, we 
will use an electronic patient tracking system. For every 
patient, a wristband with a unique ibeacon will be used 
that automatically activates recording once unwrapped by 
EMS personnel at the moment the dispatch office issues 
an ambulance for a potentially IVT/IAT-eligible patient. 
The ibeacon emits a low-voltage Bluetooth signal, which 
will be automatically picked up by fixed handhelds in the 
ambulance and premounted in-hospital tablets en route 
to IVT/IAT providing accurate, straightforward and auto-
matic data on TSD and its various subtrajectories (see 
figure 2).
TSD ends at the moment IVT/IAT is initiated. For 
TSD to IVT, this is the moment the bolus of alteplase 
is administered, whereas the endpoint for TSD to IAT 
will be groin-puncture and the last angio-run. These 
endpoints will be registered automatically once a fixed 
button in the CT-room/neuro-care unit or angiography 
suite is pushed by the treating physician. This will be 
verified for every IVT/IAT-treated patient with the 
Electronic Patient Recording (EPR). All recordings on 
patient tracking are automatically stored in a protected 
cloud.
Other data including demographics, medical history, 
EMS parameters, physical and additional test results and 
interventional features performed as part of standard 
care will be documented anonymously from the EPR.
As soon as possible after hospital admission, the patient 
or legal representative will be informed on the study and 
a deferred consent will be obtained by a local investigator.
Patients are allowed to refuse the wristband application 
without any consequences. Subjects can leave the study at 
Figure 2 Real-time audio-visual feedback intervention, throughout various pathways in acute ischaemic stroke care. Endpoint 
registration will take place through fixed real-life push buttons. CAT room, catheterisation room; ER, emergency room; IAT, intra-
arterial thrombectomy; IVT, intravenous thrombolysis.
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any time for any reason if they wish to do so without any 
consequences.
randomisation
Randomisation of the intervention (real-time audio-visual 
feedback) will be automatically generated per patient 
based on a computer algorithm. This will be prior to EMS 
distribution of (randomised) ibeacons.
Primary outcomes
TSD to IAT and TSD to IVT (minutes).
secondary outcomes
1. TSD subtrajectories: ambulance arrival at ‘scene-of-
stroke’, time spent on scene, ‘scene-of-stroke’-to-hospi-
tal time, arrival and departure from the ER, CT room, 
neuro-care unit and angiography suite.
2. Proportion of patients treated with IVT/IAT, of all 
acute ischaemic stroke patients presented to the ER 
within 4.5 hours (IVT)/6 hours (IAT) after symptom 
onset.13
3. Functional outcome (modified Rankin Scale) at 
3 months,33 evaluated through a standardised and val-
idated telephone interview by an observer blinded to 
treatment allocation.
4. Safety parameters:
i. Occurrence of symptomatic intracerebral hae-
morrhage defined as evidence of intracranial 
haemorrhage on imaging associated with neuro-
logical deterioration (an increase in NIHSS of ≥4 
points) or death.34 NIHSS is routinely performed 
by the treating physician and will otherwise be 
constructed from medical records as described 
previously.35
ii. Proportion of IVT/IAT-treated stroke mimics.
data monitoring body
No data safety monitoring board will be installed since 
the trial yields no risks for participating subjects.
Patient and public involvement
For the purpose of this study, a focus group advising in 
design, implementation and effectuation of the study 
(including patients' associations, nurses, healthcare 
insurers, PDEng clinical informatics) was created. Next 
to publications in peer-reviewed journals, a public sympo-
sium is planned to disseminate study results to patients 
and other interested parties.
sample size estimates
Sample size calculation is based on the hypothesis of an 
at least 20 min difference of TSD to IAT and an at least 
10 min difference of TSD to IVT. We think these differ-
ences are feasible based on data from MR CLEAN.2
In the MR CLEAN trial (n=500), mean TSD to IAT 
(n=233) was 256 min (SD 40). To detect a 20 min differ-
ence with a p value of 0.05 and a power of 0.8, we will 
need 63 patients in each arm. To increase power, we aim 
at including 75 IAT-patients in each arm.
In the MR CLEAN trial, mean TSD for IVT was 90 min 
(SD 35). To detect a 10 min difference of TSD to IVT with 
a p value of 0.05 and a power of 0.8, we will need 193 
IVT-patients in each arm. In clinical practice, approxi-
mately 9% of patients for whom the dispatch office issues 
an ambulance will end up being treated with IVT.19 Of 
these patients, approximately 30% will be eligible for 
IAT.2 Therefore, we expect that for the inclusion of 150 
IAT-patients EMS personnel will have to unpack a wrist-
band approximately 5000 times over an estimated study 
period of 2 years.
During a run-in phase, we will electronically collect 
additional data on treatment delays (without providing 
feedback to caregivers) to adjust sample size calculation 
if required.
statistical analyses
For all analyses involving time intervals, differences 
in time delays between randomisation groups will be 
calculated with corresponding 95% CI. Analyses will be 
performed on an intention-to-treat basis. We will perform 
subgroup analysis for IAT-patients with or without prior 
IVT, for patients within and out of office hours and for 
EMS region. We will use linear regression analysis, with 
additional log-transformation if appropriate, to adjust for 
cluster effect of EMS region and for treatment location as 
this is expected to affect TSD to IVT/IAT. If required we 
will adjust for differences in EMS response and transfer 
times due to geographically different locations of stroke. 
Through additional regression analysis, we will assess a 
possible effect of calendar time on TSD and whether such 
an effect is group-dependent.
Although randomisation is computerised and by 
chance, baseline differences may still arise between the 
two groups with possible effect on outcome measures. For 
this reason, we will collect data on other determinants of 
TSD (eg, NIHSS, time from onset of symptoms, drip-and-
ship vs mothership), and we will adjust for possible base-
line incomparability.
The total number of times the EMS dispatch office 
issues an ambulance will be used to calculate the propor-
tion of patients with a discharge diagnosis of stroke and 
the total number of IVT/IAT-treated patients in each 
group. IVT/IAT-treated patients lacking endpoint regis-
tration will be excluded from primary endpoint anal-
ysis. Exploratory analysis will be performed to relate 
TSD to clinical outcome in each group. Secondary 
outcomes will be corrected for multiple testing where 
appropriate.
Additionally, we will perform cost-effective analysis of 
the electronic tracking system including the feedback 
intervention.
dIsCussIon
With ARTEMIS, we aim to reduce TSD to IVT/IAT with 
an innovative and straightforward intervention: real-time 
audio-visual feedback to caregivers.
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The PROBE design and the open nature of our inter-
vention is pragmatic and reflects future clinical practice 
of acute stroke care. By using automatically generated 
primary outcomes (TSD to IVT/IAT; ie, time) study 
results are as valid as those derived from a double-blind 
placebo controlled trial.36
We anticipate that during the study period, treatment 
delays will decrease due to initiatives aimed to optimise 
logistics other than our intervention. Moreover, data 
accrual on treatment delays by itself could already be 
an incentive to optimise logistics. For example, DNTs 
reduced substantially after these became transparent.37 38 
However, we do not expect this to invalidate our results 
as reduction of DNT took considerably longer than the 
intended length of our study. Besides, such an effect 
would be notable in both groups. Nonetheless, we will 
compare available treatment delays before and after the 
start of ARTEMIS.
Another possible bias is that the intervention effect 
will carry over to controls. Since shifts of treatment teams 
generally occur multiple times a day, we think this is 
unlikely. Nevertheless, analyses to elucidate trends over 
time will be performed.
Also, since TSD registration depends on the unwrap-
ping of patient wristbands and pushing a fixed button, 
starting times of electronic registration will be checked 
with automatic time logs of the ambulance, and endpoint 
registration will be cross-checked with the EPR. In addi-
tion, we think that small inaccuracies can occur in both 
arms and will therefore not lead to a systematic bias in 
primary outcome.
We anticipate that the intention to speed up the logistic 
process with real-time audio-visual feedback could theoret-
ically lead to more stroke mimics being treated with IVT, 
which for this reason is one of our safety outcomes. More 
importantly, this could potentially lead to more haemor-
rhagic complications related to IVT/IAT (another safety 
outcome). However, we think this is an inherent risk related 
to treatment of patients with acute stroke, already starting 
before caregivers are involved by mass media campaigns to 
educate the public to respond rapidly to a stroke (eg, Face-
Arm-Speech-Time). Moreover, with each (existent and new) 
intervention aimed to reduce treatment delays, the acute 
stroke team should work as fast as possible while remaining 
diagnostic accuracy. In addition, this theoretical danger 
is not reflected in current practice, as shortening DNTs, 
for example, did not to lead to an increased number of 
other safety parameters such as symptomatic intracerebral 
haemorrhages.39 As for stroke mimics, a recent meta-anal-
ysis showed that IVT treatment in this group appears to be 
safe.40 Nevertheless, since it is possible that treatment of 
stroke mimics may occur in our population, for a valid TSD 
comparison, we will perform subgroup analysis on TSD in 
patients in which diagnosis of ischaemic stroke and treat-
ment have been confirmed.
Also, more patients being treated with IVT and/or IAT 
within the 4.5-hour (IVT) or 6-hour (IAT) time window 
could potentially increase mean TSD. Nonetheless, we 
think that in parallel to this, the proportion of treated 
patients within the early intervals of these time windows 
will also increase, minimising such an effect.
Finally, a potential limitation is that study results on 
TSD will particularly be applicable to areas similar to 
the Netherlands, with a highly concentrated network of 
hospitals and a relatively short ‘scene of stroke’-to-hos-
pital distance. We expect in-hospital results to be more 
widely generalisable.
Reducing treatment delays for acute stroke relies on 
team effort between various caregivers in both prehos-
pital and in-hospital trajectories. This will always carry an 
inherent risk that a chain is only as strong as its weakest 
link. Meanwhile, the total trajectory is what matters most 
to the patient, as neuronal death in stroke is critically time 
dependent.41 The intervention we investigate embodies 
the whole chain of acute stroke care, from patient’s first 
EMS contact to start of treatment. Thus, with our inter-
vention, we can establish a unique connection between 
various acute stroke team members who nowadays mainly 
work separately.
Because we do not exclude any (sub)groups of patients 
with suspected stroke and our study population encom-
passes both urban as peripheral areas, the ARTEMIS trial 
has great external validity.
Another important strength of ARTEMIS is the introduc-
tion of an innovative, accurate and straightforward tech-
nique that automatically provides healthcare professionals 
with data on important performance measures of acute 
stroke care that are currently often collected retrospectively 
in a time consuming effort at the expense of accuracy.
In addition, the introduced technique will likely also 
benefit other (neurological and non-neurological) 
patient groups for whom clinical benefits of treatment 
are time dependent.
ConClusIon
With the introduction of real-time audio-visual feedback 
through an electronic patient tracking system, we expect 
treatment delays to become more transparent, to improve 
workflow, to reduce TSD to IVT/IAT, resulting in improved 
clinical outcomes and a larger proportion of patients with 
acute ischaemic stroke eligible for treatment with IVT/IAT.
stAtus of study
First recruitment was 15 February 2018. Up to this 
moment, 63 patients received an ARTEMIS wristband.
EthICs And dIssEMInAtIon
Participating centres will have access to their own results 
and collective study results will be disseminated through 
peer-reviewed journals and (inter)national conferences.
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